SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
To: donpat who wrote (298)6/28/2006 7:45:37 PM
From: Tadsamillionaire
   of 347
 
GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
ST. LOUIS, June 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that its CEO was invited to speak at the Department of Medicine of the University of Chicago about diseases associated with the angiotensin I-converting enzyme (ACE), including avian influenza ('bird flu').

Dr. Skip Garcia, Chairman of the Medicine Department, invited GenoMed's CEO, David Moskowitz, MD, for a two day Visiting Lectureship that ended yesterday. Dr. Garcia is a world-famous lung specialist whose research group is looking for drugs to decrease the 'cytokine storm' created by the avian influenza virus.

GenoMed has filed patent applications claiming that ACE inhibitors and angiotensin II blockers can do exactly that. Furthermore, these drugs may be a near-universal viral antidote, because people who get sick from all viral diseases suffer from a 'cytokine storm.' GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal response to viral bioterrorism.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. We're extremely gratified that a world-class research institution like the University of Chicago is thinking along exactly the same lines.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (300)6/28/2006 7:46:26 PM
From: Tadsamillionaire
   of 347
 
GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
ST. LOUIS, June 26 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that it has already published why patients with diabetes and high blood pressure should be at increased risk of getting West Nile virus encephalitis.

This observation has now been made in California, New York and Texas.

The link appears to be over-activity of the angiotensin I-converting enzyme, abbreviated 'ACE.'

In 2002, GenoMed published a series of four papers showing that over- activity of ACE led to diabetes and hypertension, as well as to complications like heart and kidney disease. Using the right dose of the right ACE inhibitor, it was possible to reverse diabetic or hypertensive kidney disease for the first time.

In 2004, GenoMed published that a similar approach was successful in treating over 80% of patients with West Nile virus encephalitis. GenoMed's treatment success rate for WNV encephalitis is currently 86% (19 of 22 patients improved rapidly).

In 2003, GenoMed filed patent applications claiming that ACE inhibitors and angiotensin II blockers may be a near-universal viral antidote, because previously healthy people who get sick from nearly all viral diseases suffer from a 'cytokine storm' initiated by too much angiotensin II. Angiotensin II is made by ACE. GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal public health response to viral bioterrorism.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. It's very gratifying to get separate epidemiologic confirmation that we've discovered something huge.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen6/29/2006 4:18:21 PM
   of 347
 
(eMail): MN1.com Press Conference for GenoMed

ST. LOUIS, MO, Jun 29, 2006 – GenoMed, Inc. (PINKSHEETS: GMED) will conduct a live press conference on www.MN1.com at 9:30am Central Time Friday, June 30th, 2006. Interested parties may go to www.MN1.com and download the free player enabling them to listen in for management's review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the Internet. This should prove to be an eye-opening and enriching experience for all of those associated with GenoMed (PINKSHEETS: GMED).

About MN1.com

MN1.com is the only online destination that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and "The MicroBlog," MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.

About GenoMed

GenoMed (PINKSHEETS: GMED) is a St. Louis-based Next Generation Disease Management company that uses genomics to improve patient outcomes. Besides kidney disease, GenoMed has novel approaches to many additional diseases, including a general viral antidote. Anyone can download GenoMed's protocol for avian influenza or West Nile virus from GenoMed's website, www.genomed.com, at any time of day or night.

CONTACT: David Moskowitz MD
GenoMed, Inc.
www.genomed.com
Tel. 314-983-9938
SOURCE: GenoMed

.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (302)8/4/2006 10:26:58 PM
From: Tadsamillionaire
   of 347
 
GenoMed's First Horse Recovers Quickly from Presumed West Nile Virus Encephalitis
ST. LOUIS, July 31 /PRNewswire-FirstCall/ -- GenoMed (OTC: GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the first horse in its expanded trial for West Nile virus encephalitis recovered completely within 24 hours after starting GenoMed's treatment.

Four days ago, a horse owner in Idaho contacted GenoMed to say that her horse had begun moving much more slowly, and that the veterinarian was treating it for West Nile virus encephalitis. Only two days before, another of her horses had to be put down for presumed West Nile virus encephalitis because it could no longer lift its head and eat.

Within 24 hours of starting GenoMed's treatment, the horse was 'quick on its feet' and appeared fully recovered. The horse's prompt recovery from West Nile virus encephalitis was like that GenoMed has observed since 2003 in people, and since 2004 in birds.

GenoMed's protocol uses a class of already existing blood pressure pills to block the brain inflammation caused by West Nile virus. This disease mechanism appears to be shared by all vertebrates infected with most viruses, leading GenoMed to believe it may have found a safe, general viral antidote. For this reason, GenoMed's approach was included in the language of the Project BioShield II Act of 2005, introduced by Senators Lieberman, Hatch, and Brownback. This bill has not yet been debated in the US Senate.

GenoMed's treatment success rate for WNV encephalitis in people is currently 86% (19 of 22 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'We're delighted that our anti-viral approach appears to work in yet another species. The veterinary community already treats West Nile virus encephalitis as an excessive inflammation of the brain, and is embracing our approach far more readily than the public health community. As a result, I'm afraid that we may save more horses than people this year.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/8/2006 11:19:30 AM
   of 347
 
GenoMed's West Nile Virus Trial Endorsed by Emergency Medicine Authority

Neal Handly, MD
tel. 610.563.0664
nh28@drexel.edu

David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com

ST. LOUIS—August 8, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.


Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.

Dr. Handly said, "GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial."

Dr. Handly continued, "Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community."

About Dr. Handly

Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia, PA. He was consulted to create a state-of-the-art ER this summer in Beirut, Lebanon but has been prevented from doing so by the current hostilities.

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

.

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/8/2006 12:41:30 PM
   of 347
 
Update on GenoMed's First Horse with Presumed West Nile Virus Encephalitis

"Frog," the first horse treated with GenoMed's protocol for West Nile virus encephalitis, is about 90% recovered after 2 weeks.


His story was first aired on the 5.30 pm news yesterday on KBCI TV Channel 2, Boise, Idaho, and can be accessed at: kbcitv.com

Sincerely yours,

Dave Moskowitz MD FACP
CEO & Chief Medical Officer
GenoMed, Inc.
genomed.com
tel. 314.983.9933
dwmoskowitz@genomed.com


.

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/16/2006 11:34:33 AM
   of 347
 
GenoMed's Treatment Speeds Up Texas Policeman's Recovery from West Nile Paralysis

David W. Moskowitz MD CEO, GenoMed tel. 314.983.9933 dwmoskowitz@genomed.com

ST. LOUIS—August 16, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced that a Texas policeman with paralysis from the waist down due to West Nile virus has accelerated his recovery since starting GenoMed's treatment last week.

The patient contracted West Nile virus encephalitis a month ago. On Monday of that week he was fine, but by Friday, his legs were so weak that he could only get around by crawling. Although he was hospitalized for the next two weeks, he showed little improvement and had become discouraged.

Last week, on Thursday afternoon, August 10th, the patient and his physician began GenoMed's protocol. Two days later, on Saturday, August 12th, the patient walked with assistance for 100 steps, compared to only 18 steps on Friday, the day before. Yesterday, Tuesday, August 15th, the patient could easily move the toes in his right foot for the first time, as well as begin to move his right foot sideways.

Said GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, FACP, "This patient's accelerated recovery from West Nile virus reinforces the idea that our treatment should be used early in all patients suspected of West Nile virus encephalitis. It is possible that he might not have progressed to paralysis if his physician had started him on our treatment during the very first week of symptoms."

Added Dr. Moskowitz, "Getting the word out about our treatment may literally make the difference between life and death, or in this case a quick recovery versus prolonged paralysis."

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 87% treatment success rate (20 of 23 patients). The first 8 patients were published two years ago in a peer-reviewed medical journal, and GenoMed still has the only published treatment for West Nile virus encephalitis in the medical literature. This summer GenoMed extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

.

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/17/2006 10:52:27 AM
   of 347
 
GenoMed's Second Horse Recovers Quickly from Presumed West Nile Virus Encephalitis

David W. Moskowitz MD - GenoMed - St. Louis, Missouri - Tel. 314.983.9933 - dwmoskowitz@genomed.com
Randy Bean DVM - Owyhee Veterinary Clinic - Homedale, Idaho - Tel. 208-337-4677


ST. LOUIS—August 17, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the second horse in its expanded trial for West Nile virus encephalitis recovered completely within 72 hours after starting GenoMed's treatment.

On Saturday afternoon this past weekend, a horse owner in Idaho telephoned Dr. Randy Bean to say that his horse could no longer walk straight. The horse had not been vaccinated for West Nile virus, and the diagnosis was presumed West Nile virus encephalitis. The usual treatment for a horse with WNV costs about $700, and includes antiserum and intravenous dexamethasone. The owner didn't want to spend that much money on his horse. Dr. Bean, who had recently treated another horse with GenoMed's approach, encouraged the owner not to just let his horse die, but to try GenoMed's treatment, which costs $10 a day.

Within 72 hours, the horse was fully recovered.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. Dr. Bean feels that GenoMed's treatment made the difference, and is now calling for a wider trial of GenoMed's approach in horses.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "I'm delighted that Dr. Bean has managed to cure a second horse with presumed WNV using our approach. I'm hoping our treatment finally gets a fair trial this year."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz or Dr. Bean directly (see contact information above) to discuss specific medications and dosing.


Share RecommendKeepReplyMark as Last Read


From: jmhollen8/21/2006 10:10:06 AM
   of 347
 
GenoMed's Third Horse with Presumed West Nile Virus Encephalitis Is Better in 24 Hours

David W. Moskowitz MD
GenoMed
St. Louis, Missouri
Tel. 314.983.9938
dwmoskowitz@genomed.com

ST. LOUIS—August 21, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the third horse in its expanded trial for West Nile virus encephalitis recovered markedly within 24 hours after starting GenoMed's treatment.

On Thursday afternoon last week, a horse owner in Fresno, California telephoned GenoMed to say that her horse could no longer walk straight and was falling down. The horse had not been vaccinated for West Nile virus, and the diagnosis by the veterinarian was presumed West Nile virus encephalitis.

Within 24 hours of the first dose of GenoMed's treatment, the horse was chasing other horses away from his food, which they had been eating while he was sick.

West Nile virus encephalitis affects horses more severely than people, and the odds of recovery are slimmer. As with people, recovery from viral encephalitis usually takes at least a week. Recovery within 24 hours, like GenoMed's three horses and most of GenoMed's human patients, is extremely unusual.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "It's always thrilling to see a clinical trial showing great results. Every trial is really just a gamble. Fortunately, this one seems to be continuing to pay off. All our evidence for the past four years, in humans, birds, and now horses, has been extremely positive."

GenoMed's treatment success rate for WNV encephalitis in people is currently 87% (20 of 23 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

About GenoMed

Anyone can download the human protocol for West Nile virus for free from GenoMed's website, www.genomed.com, at any time. Horse owners are encouraged to contact Dr. Moskowitz directly (see contact information above) to discuss dosing.

.

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/29/2006 9:31:06 AM
   of 347
 
GenoMed Cleared by Indian Government to Distribute Healthcare to India

Contact:
David Moskowitz MD
CEO, GenoMed, Inc.
St. Louis, Missouri
www.genomed.com
Tel. 314-983-9933
Email: dwmoskowitz@genomed.com

Ms. Sujata Mital
Director, Sumit Biosciences Pvt Ltd.
Mumbai, India
www.sumitbiomedical.com
Email: sumit_exports@yahoo.com


ST. LOUIS, August 29, 2006 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management (DM) company whose business is public health™, announced today that it has obtained clearance, through their Indian distributor Sumit Biosciences Pvt Ltd, from the Indian Government to market its Next Generation DM™ product in India.

The cost is under US $150 per patient per year. Since the per capita income in India is around $600 a year, GenoMed's Next Generation DM™ service is well within the reach of the average Indian citizen.

Sumit Biosciences Pvt Ltd is currently enlisting physicians at the King Edward Memorial Hospital in Mumbai to offer GenoMed's protocols to their patients. Mumbai, formerly called Bombay, is the fourth largest city in the world, with 12 million inhabitants.

Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "The US and Europe have been completely uninterested in our published methods for preventing kidney dialysis and slowing down emphysema. The $25 billion a year that the US spends on dialysis may actually serve as a perverse financial disincentive not to eliminate the industry. India spends nothing on dialysis, so nobody there has a financial stake in preserving the dialysis industry."

Added Dr. Moskowitz, "It's as if the Directors of the TB sanitaria in the US ignored streptomycin in 1950 to save their jobs. It's a shame that the taxpayers of the US and Europe are paying for genomics-based medicine, but citizens of developing countries like India are the only ones using it."

About GenoMed™

GenoMed is the only biotechnology company serious about both lowering healthcare costs and improving patient outcomes. It is leading the clinical revolution made possible by knowing which genes cause which diseases. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip®, on a research basis only, to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in Caucasians. And GenoMed is in the process of creating a virtual pharmaceutical company to develop new drugs for the hundreds of cancer chemotherapy targets it has discovered, where no drug yet exists.

.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10